Logo

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Share this

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Shots:

  • The P-III STR1VE study involves assessing of Zolgensma in 22 patients with SMA Type1 + one or two copies of the SMN2 backup gene + bi-allelic SMN1 gene deletion or point mutations aged < 6mos. at the time of gene therapy
  • The P-III STR1VE study results: alive patients (95%); patients reached 10.5mos. (86%); CHOP-INTEND score increases @1 & 3mos. after gene transfer (7 & 11.8 points);  8 patients could sit without support for 30sec. (median-age 12.5 mos.) with expected completion in 2020
  • Zolgensma (onasemnogene abeparvovec-xioi- one-time infusion) is a gene therapy which introduces the copy of SMN gene using AAV9 and has received FDA’s BT designation & PR with an expected action date in May- 2019 and approval in Japan & EU in H2’19

Ref: Novartis | Image: Talkmarket

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions